DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Contribución de congreso (ConferenceOutput)
The basal ganglia: a new possible therapeutic target in the Allan-Herndon-Dudley Syndrome
Resumen del póster presentado al 3rd Symposium on Biomedical Research: "Advances and Perspectives in Neuroscience", celebrado en la Universidad Autónoma de Madrid el 22 de abril de 2016., The Allan-Herndon-Dudley syndrome (AHDS) is a rare disease caused by mutations in
the gene SLC16A2, which codifies for the monocarboxylate transporter 8 (MCT8), the
solely cell-membrane transporter that specifically transports thyroid hormones. The altered expression of the mutated MCT8 causes peripheral hyperthyroidism and brain hypothyroidism, which is thought to be the cause of the neurological phenotype in AHDS patients that includes mental and developmental retardation, hypotonia and in
most of the cases epilepsy. These clinical features start early in the infancy and develop in the adulthood to spastic tetraplegia and paroxysmal dyskinesia. The mechanisms underlying the disease are unknown so far and there is not an effective treatment. In this study, we have focused our work on the basal ganglia, as they are part of the motor voluntary movement controlling system. We have analyzed human paraffin-embedded brain sections of the basal ganglia taken from necropsies of AHDS patients and controls by immunohistochemistry for detection of MCT8, some of the characteristic markers of striatal neural populations (enkephalin and choline acetyltransferase) and other markers of synapsis (synaptophysin) or damage.
We have observed an alteration of the basal ganglia circuitry based on the abnormal
expression pattern of enkephalin and choline acetyltransferase in the striatum of the
AHDS patients. We have also observed alterations in the synaptophysin staining in
patients versus control basal ganglia. These results indicate that the basal ganglia are
severely affected by mutations in MCT8 and that structural and functional alterations in
this region could be the cause of some clinical features found in AHDS patients, which
suggests that those areas could be considered therapeutic targets in AHDS., Supported by grants from the Spanish Ministry of Economy and Competitiveness
(MINECO) SAF2014-54919-R., Peer Reviewed